Reductions in OFF Time with ND0612 For Patients with Parkinson's Disease Experiencing Motor Fluctuations: Responder-Analysis from an Open-Label Phase 2 Study

被引：0
|
作者：
Ellenbogen, A.
Espay, A.
Isaacson, S.
Lopes, N.
Sasson, N.
Yardeni, T.
Poewe, W.
机构：
来源：
MOVEMENT DISORDERS | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
46
引用
收藏
页码：S20 / S21
页数：2
相关论文
共 50 条
  • [1] First results for the BeyoND study: A phase 2b, international, open-label study evaluating long-term safety of ND0612 in patients with Parkinson's disease experiencing motor complications
    Poewe, W.
    Stocchi, F.
    Giladi, N.
    Adar, L.
    Rosenfeld, O.
    Oren, S.
    Olanow, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 63 - 63
  • [2] ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study
    Giladi, Nir
    Gurevich, Tanya
    Djaldetti, Ruth
    Adar, Liat
    Case, Ryan
    Leibman-Barak, Shelly
    Sasson, Nissim
    Caraco, Yoseph
    PARKINSONISM & RELATED DISORDERS, 2021, 91 : 139 - 145
  • [3] CONTINUOUS SUBCUTANEOUS LEVODOPA/CARBIDOPA INFUSION WITH ND0612 FOR PARKINSON'S DISEASE: THREE-YEAR DATA FROM THE OPEN-LABEL BEYOND STUDY
    Stocchi, F.
    Poewe, W.
    Ellenbogen, A.
    Adar, L.
    Salin, L.
    Case, R.
    Yardeni, T.
    Giladi, N.
    PARKINSONISM & RELATED DISORDERS, 2024, 122
  • [4] CONTINUOUS SUBCUTANEOUS LEVODOPA/CARBIDOPA INFUSION (ND0612) FOR PATIENTS WITH PARKINSON'S DISEASE AND MOTOR FLUCTUATIONS: A PHASE 3, ACTIVE-CONTROLLED STUDY (BOUNDLESS)
    Stocchi, F.
    Espay, A.
    Albanese, A.
    Ellenbogen, A.
    Ferreira, J. J.
    Giladi, N.
    Gurevich, T.
    Hassin-Baer, S.
    Hernandez-Vara, J.
    Isaacson, S.
    Kieburtz, K.
    LeWitt, P.
    Lopez-Manzanares, L.
    Olanow, C. W.
    Pahwa, R.
    Poewe, W.
    Sarva, H.
    Yardeni, T.
    Adar, L.
    Lopes, N.
    Sasson, N.
    Case, R.
    Rascol, O.
    PARKINSONISM & RELATED DISORDERS, 2024, 122
  • [5] First Results for The BeyoND Study: An open-label international, multicenter study evaluating the long-term safety of ND0612 in patients with idiopathic Parkinson's disease
    Isaacson, Stuart
    Poewe, Werner
    Simuni, Tanya
    Oren, Sheila
    Case, Ryan
    Olanow, C. Warren
    NEUROLOGY, 2020, 94 (15)
  • [6] The BouNDless Study: An Active-Controlled, Randomized, Double-Blind, Double-Dummy Phase 3 Study of Continuous ND0612 Infusion in Patients with Parkinson's Disease Experiencing Motor Fluctuations
    Espay, Alberto
    Rascol, Olivier
    Yardeni, Tamar
    Adar, Liat
    Rosenfeld, Olivia
    Case, Ryan
    Olanow, C. Warren
    NEUROLOGY, 2020, 94 (15)
  • [7] Efficacy of ND0612 a 24-hour Subcutaneous LevodopaCarbidopa Infusion for People with Parkinson's Disease Experiencing Motor Fluctuations: Subgroup-Analyses from a Randomized, Controlled Phase 3 Study
    Harrison, Antoinette
    Poewe, Werner
    Lopes, Nelson
    ANNALS OF NEUROLOGY, 2024, 96 : S219 - S220
  • [8] Clinical Experiences With Levodopa Methylester (Melevodopa) in Patients With Parkinson Disease Experiencing Motor Fluctuations: An Open-Label Observational Study
    Zangaglia, Roberta
    Stocchi, Fabrizio
    Sciarretta, Massimo
    Antonini, Angelo
    Mancini, Francesca
    Guidi, Marco
    Martignoni, Emilia
    Pacchetti, Claudio
    CLINICAL NEUROPHARMACOLOGY, 2010, 33 (02) : 61 - 66
  • [9] Pharmacokinetic profile of ND0612 (levodopa/carbidopa for subcutaneous infusion) in Parkinson's disease (PD) patients with motor fluctuations: results of a phase IIa dose finding study
    Giladi, N.
    Caraco, Y.
    Gurevich, T.
    Djaldetti, R.
    Cohen, Y.
    Yacobi-Zeevi, O.
    Oren, S.
    Kieburtz, K.
    Olanow, C. W.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 66 - 66
  • [10] Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study
    Reichmann, Heinz
    Lees, Andrew
    Rocha, Jose-Francisco
    Magalhaes, Diogo
    Soares-da-Silva, Patricio
    TRANSLATIONAL NEURODEGENERATION, 2020, 9 (01)
12345